Skip to main content

Table 7 Tacrolimus pharmacokinetic data in relation to CYP3A5 gene polymorphisms in the 8 patients with acute rejection (AR)

From: CYP and SXR gene polymorphisms influence in opposite ways acute rejection rate in pediatric patients with renal transplant

  Days AA/AG with AR (5 patients) GG with AR (3 patients) AA/AG without AR (7 patients)
Dose/kg (mg/kg) day 7 0.14 ± 0.01 0.11 ± 0.05 0.19 ± 0.14
day 30 0.20 ± 0.03* 0.09 ± 0.03 0.18 ± 0.13
day 90 0.14 ± 0.05* 0.08 ± 0.01 0.16 ± 0.12
day 80 0.13 ± 0.04* 0.06 ± 0.01 0.14 ± 0.10
day 360 0.10 ± 0.04 0.05 ± 0.02 0.13 ± 0.10
C0/(dose/kg) (ng/ml)/(mg/kg) day 7 55.56 ± 20.87 175.42 ± 120.49 74.92 ± 62.45
day 30 45.81 ± 10.91 *# 105.81 ± 47.40 92.53 ± 49.62
day 90 63.92 ± 26.57*# 126.11 ± 54.57 110.56 ± 55.25
day 180 55.33 ± 23.42* 134.14 ± 77.98 79.78 ± 35.21
day 360 79.48 ± 49.34 121.85 ± 50.87 66.35 ± 37.25
  1. Data are expressed as mean ± s.d. Mann Whitney was used as statistical test
  2. * p-value < 0.05 AA/AG vs GG patients with acute rejections
  3. # p-value < 0.05 AA/Ag with acute rejection vs AA/AG without acute rejection